Breast Cancer Brachytherapy Market Size, Share & Trends Analysis Report By Technology (High Dose Rate, Low Dose Rate), By Region (North America, Europe, Asia Pacific, Latin America, MEA), And Segment Forecasts, 2020 - 2027

Report Overview 

The global breast cancer brachytherapy market size was valued at USD 61.5 million in 2019 and is expected to grow at a compound annual growth rate (CAGR) of 7.0% from 2020 to 2027. The rising prevalence of breast cancer is expected to accelerate market growth. According to the estimates of the American Cancer Society, in 2020, 279,100 new breast cancer cases were diagnosed and around 42,690 deaths are expected to occur in the U.S. alone. The presence of various non-profit organizations such as the National Breast Cancer Foundation, Inc., Indian Cancer Society, Breastcancer.org, and many others are anticipated to drive the market. These organizations are involved in raising awareness about early detection and diagnosis and are improving the quality of life.

Moreover, supportive initiatives undertaken by companies and non-profit organizations in providing a better life to people are expected to boost the market. For instance, in October 2019, Merit Medical and Breastcancer.org entered into a partnership and donated USD 32,000 to the organization to reduce the incidence rate. The company offered innovative solutions for the treatment of the targeted disease using brachytherapy and other modalities.

Furthermore, in September 2019, the Islamic Development Bank (IsDB) with the International Atomic Energy Agency (IAEA) launched “The Partnership Initiative” to raise funds for the projects that are helping low and middle-income countries fight against cancer affecting women (particularly breast and cervical cancer) every year. Since 2013, IsDB has approved loans worth USD 364 million and grants for cancer control programs in 17 countries which are members of both IsDB and IAEA

In addition, the integration of HDR brachytherapy with other radiation therapies to enhance the efficacy and effectiveness of the treatment is anticipated to drive the market growth. For instance, an ongoing clinical trial at the University of Virginia evaluated the efficacy of Intraoperative Radiation Therapy (IORT) with CT-Guided HDR Brachytherapy to treat breast cancer at the time of Breast Conserving Surgery (BCS).

Technology Insights

The HDR brachytherapy segment accounted for the largest revenue share of over 65.0% in 2019 and is projected to be the fastest-growing segment over the forecast period. This is owing to the wide use of brachytherapy systems such as Mammosite, Savi, iCAD eBX, and Contura.

Brachytherapy for breast cancer involves different techniques for placing devices such as interstitial brachytherapy and intracavitary brachytherapy. The most commonly performed technique for breast cancer is intracavitary brachytherapy. The presence of a wide range of products and instruments such as SagiNova is expected to boost the market.

Furthermore, better dose coverage, decreased radiation exposure, high dose of radiation for a shorter period of time, and improved convenience of treatment delivery are some of the major factors attributed to accelerating segment growth.

In addition, increasing the adoption of breast HDR brachytherapy at hospitals and cancer care centers is expected to fuel segment growth. For instance, in November 2019, the SagiNova HDR afterloader system developed by Eckert and Ziegler BEBIG had extended its presence in various radiation oncology centers of Brazil after it received approval from Agência Nacional de Vigilância Sanitária (ANVISA).

Regional Insights

In North America, the market accounted for the largest revenue share of over 50.0% in 2019, owing to the presence of major players, increasing prevalence of the disease, established healthcare facilities, and high healthcare expenditure in the region. Furthermore, the rising adoption of brachytherapy over conventional methods for safer and efficient breast cancer treatment is attributed to the highest share.

In addition, the presence of favorable reimbursement policies for patients, hospitals, and oncologists is expected to boost the growth of the market in the region. For instance, the Medicare reimbursement of HDR brachytherapy is USD 11,000 under the coding of Centers for Medicare and Medicaid Services (CMS). 

In Asia Pacific, the market is expected to witness a CAGR of 8.3% over the forecast period, owing to the presence of a large target population. The incidence is growing rapidly pertaining to an unhealthy lifestyle. In addition, Japan dominated the market in 2019 due to the presence of advanced technologies and is the most developed country in the Asia Pacific region.

However, India and China are estimated to show lucrative growth over the forecast period owing to the presence of huge opportunities for new investors and companies. A large number of companies is focusing on the expansion of their business in the Asian region. For instance, in August 2017, iCAD received CFDA (China Food and Drug Administration) approval (now known as The National Medical Products Administration (NMPA)) for its Xoft Axxent balloon applicators used in breast cancer brachytherapy treatment.

Key Companies & Market Share Insights

The key players in the market are Elekta AB, Eckert & Ziegler BEBIG, Varian Medical Systems, Inc., and others. These players held the majority of shares in the market. They already have a well-established network of suppliers and customers, which helps in strengthening their market position. Many companies are engaged in undertaking strategic initiatives such as collaborations, new product launches, mergers and acquisitions, and partnerships to gain market share and increase the penetration of their products. For instance, in November 2018, Merit Medical completed the acquisition of Cianna Medical and will market Cianna’s wire-free breast localization products (Savi Brachy and Scout) used for the treatment of breast cancer. Some of the prominent players in the breast cancer brachytherapy market include:

• Eckert & Ziegler BEBIG

• Elekta AB

• Varian Medical Systems, Inc.

• ICAD, INC.

• Hologic, Inc.

• Cianna Medical

Breast Cancer Brachytherapy Market Report Scope

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2027. For the purpose of this study, Grand View Research has segmented the global breast cancer brachytherapy market report on the basis of technology and region:

• Technology (Revenue, USD Million, 2016 - 2027)

  • High-Dose Rate

  • Low-Dose Rate

• Regional Outlook (Revenue, USD Million, 2016 - 2027)

  • North America

    • The U.S.

    • Canada

  • Europe

    • The U.K.

    • Germany

    • France

    • Italy

    • Spain

    • Russia

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Australia

    • Singapore

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • MEA

    • South Africa

    • Saudi Arabia

    • UAE